Cellular HIV-1 DNA levels in drug sensitive strains are equivalent to those in drug resistant strains in newly-diagnosed patients in Europe
- Authors: Balotta C, Clotet B, Demetriou VL, Grossman Z, Jørgensen LB, Kostrikis LG, Kousiappa I, Lepej SZ, Levy I, Nielsen C, Paraskevis D, Poljak M, Roman F, Ruiz L, Schmidt JC, Van de Vijver DA, Vercauteren J, Vandamme AM, Van Laethem K
- Journal: PLoS One
- Link: http://www.ncbi.nlm.nih.gov/pubmed/20544014
BACKGROUND:
HIV-1 genotypic drug resistance is an important threat to the success of antiretroviral therapy and transmitted resistance has reached 9% prevalence in Europe. Studies have demonstrated that HIV-1 DNA load in peripheral blood mononuclear cells (PBMC) have a predictive value for disease progression, independently of CD4 counts and plasma viral load.
Read More
Treatment-associated polymorphisms in protease are significantly associated with higher viral load and lower CD4 count in newly diagnosed drug-naive HIV-1 infected patients.
- Authors: Albert J, Åsjö B, Balotta C, Boucher CA, Bruckova M, Camacho RJ, Clotet B, Coughlan S, Deforche K, Grossman Z, Hamouda O, Horban A, Korn K, Kostrikis LG, Kücherer C, Libin P, Liitsola K, Nielsen C, Paraskevis D, Poljak M, Puchhammer-Stöckl E, Riva C, Ruiz L, Schmit JC, Schuurman R, Sönnerborg A, SPREAD-programme, Staneková D, Stanojevic M, Struck D, Theys K, Van de Vijver DA, Van Laethem K, Vandamme AM, Vercauteren J, Wensing AMJ
- Journal: Retrovirology
- Link: http://www.ncbi.nlm.nih.gov/pubmed/?term=Treatment-associated+polymorphisms+in+protease+are+significantly+associated+with+higher+viral+load+and+lower+CD4+count+in+newly+diagnosed+drug-naive+HIV-1+infected+patients
BACKGROUND:
The effect of drug resistance transmission on disease progression in the newly infected patient is not well understood. Major drug resistance mutations severely impair viral fitness in a drug free environment, and therefore are expected to revert quickly. Compensatory mutations, often already polymorphic in wild-type viruses, do not tend to revert after transmission.
Read More
HIV-1 transmitted drug resistance in Latin America and the Caribbean: what do we know?
- Authors: Bello DC, Gomez-Lopez A, Pineda-Peña AC, Sussmann O, Van Laethem K, Vandamme AM, Vercauteren J
- Link: http://www.ncbi.nlm.nih.gov/pubmed/?term=HIV-1+Transmitted+Drug+Resistance+in+Latin+America+and+the+Caribbean%3A+What+Do+We+Know%3F
Latin America and the Caribbean countries have increased the scaling-up of antiretroviral treatment in the last years. The increase of transmitted drug resistance has been feared due to the worrisome indicators associated with the emergence of drug resistance and monitored by the World Health Organization (WHO). Consequently, our aim was to review all relevant studies […]
Read More
The demise of multidrug- resistant HIV-1: The national time trend in Portugal
- Authors: Aguas MJ, Camacho RJ, Carvalho AP, Duque LM, Faria D, Faria T, Mansinho K, Peres S, Teófilo E, Theys K, Valadas E, Vandamme AM, Vera J, Vercauteren J
- Journal: Journal of Antimicrobial Chemotherapy
- Link: http://www.ncbi.nlm.nih.gov/pubmed/23228933
Despite a decreasing mortality and morbidity in treated HIV-1 patients, highly active antiretroviral treatment (HAART) can still fail due to the development of drug resistance. Especially, multidrug-resistant viruses pose a threat to efficient therapy. We studied the changing prevalence of multidrug resistance (MDR) over time in a cohort of HIV-1-infected patients in Portugal.
Read More